Kirby J. Eng, RPh

Executive Director, Business Development, PharMedQuest

Authored Items

Emerging Tools for Assessing Value: Pros and Cons

August 2015, Vol 6, No 7 - VBCC Perspectives

The emergence of various tools for assessing value or, more to the point, drug costs—both direct and indirect—by leaders within the oncology and hematology community is highly commendable. Those of us on the managed care side of healthcare look forward to practical and meaningful tools in helping patients, pro­viders, employers, and health plans navigate through the complexity of oncology drug therapy and drive better informed decision-making. [ Read More ]